Mindstrong, Inc.

Mindstrong has developed the first ever digital brain biomarkers applying machine intelligence to human-computer interaction patterns that can be captured passively from cellphone use. Mindstrong's patented digital biomarkers and digital phenotyping will for the first time enable ecological and continuous measure of neuropsychological function, providing physicians, healthcare systems and payers insight not previously possible and empowering care teams to better diagnose and treat neuropsychiatric and neurodegenerative conditions. Mindstrong is showing that individual smartphone behavior may be able to reliably predict the onset of suicidal tendencies, significant depression, schizophrenia breaks, or the signs of mania experienced by those with bipolar disorder. Mindstrong also believes its apps may have much broader implications by characterizing what makes each of us mentally unique (endophenotype) and mapping our mental uniqueness to our physical health.